Warrant Agreement to Purchase Shares of Preferred Stock, Hercules Technology



 Exhibit 10.30 
 Execution Version 
 THE WARRANT PROVIDED FOR IN THIS AGREEMENT AND THE
SECURITIES ISSUABLE UPON EXERCISE OF SUCH WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 
 To Purchase Shares of the Preferred Stock of 
 AVEO PHARMACEUTICALS, INC. 
 Dated as of March 29, 2006 (the “Effective Date”) 
 WHEREAS, AVEO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has entered into a Senior Loan and Security
Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”); 
 WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for
in the Loan Agreement, the right to purchase shares of its Preferred Stock pursuant to this Warrant Agreement (the “Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual
covenants and agreements contained herein, the Company and Warrantholder agree as follows: 
 SECTION 1. GRANT OF THE RIGHT TO PURCHASE
PREFERRED STOCK. 
 For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon
the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, (i) up to Eight Hundred Twenty Four Thousand Six Hundred Twenty Five and No/Dollars ($824,625.00) in fully paid and non-assessable
shares of the Preferred Stock (as defined below) at the Exercise Price (as defined below) effective upon the Effective Date and (ii) up to Two Hundred Seventy Four Thousand Eight Hundred Seventy Five and No/Dollars ($274,875.00) in fully paid
and non-assessable shares of the Preferred Stock at the Exercise Price effective, without further action, upon the Company drawing more than $7,500,000 under the Loan Agreement. As used herein, the following terms shall have the following meanings:

 “1934 Act” has the meaning given to it in Section 10(d). 
 “Acknowledgment of Exercise” has the meaning given to it in Section 3(a). 
 “Act” means the Securities Act of 1933, as amended. 
 “Charter” means the Company’s Articles of Incorporation, Certificate of Incorporation or other constitutional document,
as may be amended from time to time. 








 Execution Version 
  

 “Common Stock” means the Company’s common stock, $.001 par value
per share. 
 “Exercise Price” means (i) $3.00 per share in the event that the Warrant provided for in this
Agreement is exercisable for shares of Series C Preferred Stock or (ii) the purchase price per share of Series D Preferred Stock paid by investors in the Series D Preferred Stock Financing in the event that the Warrant provided for in this
Agreement is exercisable for shares of Series D Preferred Stock. The Exercise Price is subject to adjustment as provided in Section 8. 
 “Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a registration statement under the Act, which public offering has
been declared effective by the Securities and Exchange Commission (“SEC”). 
 “Lock-Up
Threshold” means at such time when the (i) the Company’s capital stock actually held by Warrantholder and (ii) Preferred Stock exercisable pursuant to the Warrant, in the aggregate, exceeds 1% of the Common Stock of the
Company on a as converted basis. 
 “Merger Event” means a merger or consolidation involving the Company in
which (x) the Company is not the surviving entity, or (y) the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital of another entity. 
 “Net Issuance” has the meaning given to it in Section 3(a). 
 “Notice of Exercise” has the meaning given to it in Section 3(a). 
 “Preferred Stock” means Series C Preferred Stock or, in the event that the purchase price per share of Series D Preferred
Stock paid by investors in the Series D Preferred Stock Financing is less than $3.00 per share, Series D Preferred Stock, and any other stock into or for which the Series C Preferred Stock or Series D Preferred Stock, as applicable, may be converted
or exchanged, and upon and after the occurrence of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred Stock, including, without
limitation, the consummation of an Initial Public Offering in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or retired, “Preferred Stock” shall mean such Common
Stock. 
 “Purchase Price” means, with respect to any exercise of the Warrant provided for in this Agreement, an
amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock to be acquired under this Agreement pursuant to such exercise. 
 “Series C Preferred Stock” means the Series C Convertible Preferred Stock, $.001 par value per share, of the Company.

 “Series D Preferred Stock” means the preferred stock issued pursuant to the Series D Preferred Stock
Financing. 
 “Series D Preferred Stock Financing” the first issuance of preferred stock by the Company to bona
fide institutional investors after the Effective Date. 
 “Transfer Notice” has the meaning given to it in
Section 11. 
 “Warrant” has the meaning given to it in Section 2. 
 In addition, capitalized terms used herein but not otherwise defined herein shall have the meaning assigned to such terms in the Loan Agreement. 

 

 2 









 Execution Version 
  

 SECTION 2. TERM OF THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein (the
“Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon the earliest to occur of (i) seven (7) years from the Effective Date; or (ii) three (3) years after the Initial
Public Offering. 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 
 (a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time,
or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of
Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) business days thereafter,
the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of
Exercise”) indicating the number of shares which remain subject to future purchases, if any. 
 The Purchase Price may
be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Agreement (“Net Issuance”). If the
Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

			
	X =	  	Y (A-B)
		  	    A

  

					
	Where:    	  	X  =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  		  	 Y = the number of shares of Preferred Stock requested to be exercised under this Agreement (including the number of shares to be cancelled in
payment of the Purchase Price).

			
		  		  	 A = the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.

			
		  	B  =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock
shall mean with respect to each share of Preferred Stock: 
 (i) if the exercise is in connection with an initial
Public Offering, and if the Company’s registration statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to
Public” of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 
 (ii) if the exercise is after, and not in connection with an Initial Public Offering, and: 
 (A) if the Common Stock is traded on a securities exchange or the Nasdaq National Market, the fair market value shall be
deemed to be the product of (x) the average of the closing prices over a five (5) day period ending three days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common
Stock into which each share of Preferred Stock is convertible at the time of such exercise; or 
  

 3 









 Execution Version 
  

 (B) if the Common Stock is traded over-the-counter, the fair market
value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted over the five (5) day period ending three days before the day the current fair market value of the securities is being determined and
(y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 
 (iii) if at any time the Common Stock is not listed on any securities exchange or NASDAQ National Market or quoted in the over-the-counter market, the current fair market value of Preferred Stock shall be
the product of (x) the fair market value of Common Stock as determined in good faith by the Company’s Board of Directors (provided, that if Warrantholder disagrees with the fair market value determined by the Company’s Board of
Directors Warrantholder may solicit, from an appraiser reasonably acceptable to the Company, an independent appraisal of the fair market value of the Common Stock and, if such valuation is higher, Warrantholder’s may substitute the Board of
Director’s fair market value price with that of the independent appraiser) and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise, unless the Company shall become
subject to a Merger Event pursuant to which the Company is not the surviving party, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Company’s Preferred Stock on a
common equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company
shall indicate on the Acknowledgement of Exercise the remaining number of shares purchasable hereunder. All other terms and conditions of this Agreement following the date of such partial exercise shall be identical to those contained herein,
including, but not limited to the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this
Agreement is not previously exercised as to all Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically
exercised pursuant to Section 3(a) (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant
to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if
any, the Warrantholder is to receive by reason of such automatic exercise. 
 SECTION 4. RESERVATION OF SHARES. 
 Promptly following, and in any event within thirty (30) days of, the determination of whether the Warrant provided for hereunder shall
be exercisable for Series C Preferred Stock or Series D Preferred Stock the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to purchase Preferred
Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the Preferred Shares available hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 
 No fractional shares or scrip representing fractional shares shall be issued upon the exercise the Warrant provided for in this Agreement, but in lieu of such fractional shares the Company shall make a
cash payment therefor upon the basis of the fair market value of the share then in effect. 
  

 4 









 Execution Version 
  

 SECTION 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 
 This Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder/stockholder of the Company prior to
the exercise of the Warrant. 
 SECTION 7. WARRANTHOLDER REGISTRY. 
 The Company shall maintain a registry showing the name and address of the registered holder of the Warrant. Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(g). Warrantholder may change such address by giving written notice of such changed address to the Company. 
 SECTION 8. ADJUSTMENT RIGHTS. 
 The Exercise Price and the number of shares
of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. If at any time there
shall be a Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of the Warrant, the kind, amount and value of shares of preferred stock or
other securities or property of the successor, surviving or purchasing corporation resulting from, or participating in, such Merger Event that would have been issuable if Warrantholder had exercised the Warrant immediately prior to the Merger Event.
In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after
the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price) shall be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger
Event, upon the closing thereof, the successor, surviving or purchasing entity shall assume the obligations of this Agreement. The provisions of this Section 8(a) shall similarly apply to successive Merger Events. In connection with a Merger
Event and upon Warrantholder’s written election to the Company, the Company shall cause the Warrant to be exchanged for the consideration that Warrantholder would have received if Warrantholder chose to exercise its right to have shares issued
pursuant to the Net Issuance provisions of this Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration. 
 (b) Reclassification of Shares. Except as set forth in Section 8, if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change
any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other
change. 
 (c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred
Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased. 
  

 5 









 Execution Version 
  

 (d) Stock Dividends. If the Company at any time while the Warrant is outstanding
and unexpired shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then
the Exercise Price shall be adjusted, from and after the dale of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of
determination by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of
shares of Preferred Stock outstanding immediately after such dividend or distribution; or 
 (ii) make any other
distribution with respect to the Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made
by the Company such that the Warrantholder shall receive upon exercise of the Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as
of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 
 (e)
Antidilution Rights. Antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the Company’s Charter, and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall
promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred
Stock as of the date hereof unless such amendment, modification or waiver affects the rights of Warrantholder with respect to the Preferred Stock in the same manner as it affects all other holders of Preferred Stock. The Company shall, on a
quarterly basis, provide Warrantholder with the capitalization of the Company in writing including the total number of shares, warrants and options outstanding at the end of such quarter. For the avoidance of doubt, there shall be no duplicate
anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection (d) and the Company’s Charier. 
 (f) Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock, cash, property or other securities (assuming Warrantholder consents to a dividend involving cash,
property or other securities under the Loan Agreement); (ii) the Company shall offer for subscription prorata to the holders of any class of its Preferred Stock any additional shares of stock of any class or other rights; (iii) there shall
be any Merger Event; (iv) there shall be an Initial Public Offering; (v) the Company shall sell, lease, license or otherwise transfer all or substantially all of its assets; or (vi) there shall be any voluntary dissolution,
liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least fifteen (15) days’ prior written notice of the date on which the books of the Company shall
close or a record shall be taken for such dividend, distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event,
dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, license or other transfer of all or substantially all of the Company’s assets, dissolution, liquidation or winding up, at least fifteen
(15) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable
upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company shall give the Warrantholder at least fifteen (15) days’ written notice prior to the effective date
thereof. 
  

 6 









 Execution Version 
  

 Each such written notice shall set forth, in reasonable detail, (i) the event
requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been
adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall only be provided in the manner set forth in Section 12(g)(i). 
 (g) Timely Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Warrantholder to retain
the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder. 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 
 (a) Reservation of Preferred
Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been or, in accordance with Section 4, will be duly and validly reserved and, when issued in accordance with the provisions of this Agreement, will be
validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on
transfer under state and/or federal securities laws or in this Agreement. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Preferred
Stock upon exercise of the Warrant and payment of the Purchase Price shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related
issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the
Warrantholder. 
 (b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of
all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action
on the part of the Company. The execution and delivery by the Company of this Agreement: does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it;
and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes the legal, valid and
binding agreement of the Company, enforceable in accordance with its terms. 
 (c) Consents and Approvals. No consent or
approval of, giving of notice to, registration with, or taking of any other action in respect of, any state, federal or other governmental authority or agency is required on the part of the Company with respect to the execution, delivery and
performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be made by the time required
thereby. 
 (d) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other shares
of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other outstanding securities were issued in full compliance with all
federal and state securities laws. In addition, as of the date immediately preceding the Effective Date: 
 (i)
The authorized capital stock of the Company consists of (A) 53,996,819 shares of Common Stock, of which 5,281,473 shares are issued and outstanding, (B) 12,448,000 shares of Series A Preferred Stock, of which 12,400,000 shares are issued
and outstanding, (C) 27,215,385 shares of Series B Preferred Stock, of which 26,906,354 shares are issued and outstanding and (D) 2,333,334 shares of Series C Preferred Stock, of which 2,333,334 shares are issued and outstanding. Each
share of Series C Preferred is currently convertible into one share of Common Stock. 
  

 7 









 Execution Version 
  

 (ii) The Company has reserved 7,860,000 shares of Common Stock for
issuance under its stock option plan(s), under which 6,042,726 options are outstanding. Other than the options referred to in the prior sentence and warrants to purchase 500,000 shares of Common Stock, 48,000 of Series A Preferred Stock and 100,000
shares of Series B Preferred Stock, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other
securities of the Company. 
 (iii) In accordance with the Company’s Charter, no stockholder of the Company
has preemptive rights to purchase new issuances of the Company’s capital stock that have not been properly waived in connection with the issuance of the Warrant or the Preferred Stock to be issued upon the exercise of the Warrant. 

(e) Insurance. The Company has in full force and effect insurance policies, with extended coverage, insuring the Company and its
property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and similarly situated and as otherwise may be required pursuant to the terms of any other contract or
agreement. 
 (f) Other Commitments to Register Securities. Except as set forth in this Agreement, the Charter and the
Second Amended and Restated Investor Rights Agreement dated as of April 13, 2005, as amended, by and among the Company and the other parties thereto, there is no agreement between the Company and any holders of its securities under which the
Company has any obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (g) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of the Warrant, and the issuance of
the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of the Act and (ii) the qualification requirements of the applicable state securities laws.

 (h) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this
Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within ten days after
receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 
 (i) Information Rights. During the term of this Warrant, Warrantholder shall be entitled to the information rights contain in
Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a
Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder as been repaid. 
  

 8 









 Execution Version 
  

 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 
 This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:

 (a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the
Warrantholder’s rights contained herein has been, and such shares will be, acquired for investment and not with a view to, or for sale in connection with, the distribution of any part thereof, and the Warrantholder has no present intention of
selling or engaging in, or any agreement, undertaking or commitment with respect to, any public distribution of the same. 
 (b)
Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance
contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10.

 (c) Financial Risk. The Warrantholder has sufficient knowledge and experience in financial and business matters as to
be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment, in the Company. Such Warrantholder has made detailed inquiry concerning the Company, its business and its personnel
and the officers of the Company have made available to such Warrantholder any and all written information which it has requested and have answered to such Warrantholder’s satisfaction all inquiries made by such Warrantholder. 
 (d) Risk of No Registration. The Warrantholder understands that if the Company does not register shares of its capital stock with the
SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering shares of its capital stock under the
Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for
an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under
the Act may be made only in accordance with the terms and conditions of that Rule. 
 (e) Accredited Investor.
Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation D, as presently in effect, under the Act. 
 (f) Agreement in Connection with Initial Public Offering. Warrantholder agrees, in connection with the Initial Public Offering, (i) not to sell, make short sale of, loan, grant any options for
the purchase of, or otherwise dispose of any shares of capital stock held by the Warrantholder (other than any shares included in the offering) without the prior written consent of the Company or the underwriters managing such offering for a period
of 180 days from the effective date of such registration statement, and (ii) to execute any agreement reflecting clause (i) above as may be requested by the Company or the managing underwriters at the time of such offering;
provided, however, the foregoing provision shall only become effective if and when (A) the Lock-up Threshold occurs and (B) all persons entitled to registration rights with respect to shares of Common Stock, all other persons
selling shares of Common Stock in such offering, all persons holding in excess of one percent (1%) of the Common Stock of the Company on a as converted basis and all executive officers and directors of the Company shall also have agreed not to
sell publicly their Common Stock under the circumstances and pursuant to the terms set forth in this Section 10(f). 
  

 9 









 Execution Version 
  

 SECTION 11. TRANSFERS. 
 Subject to compliance with the provisions of this Agreement and applicable federal and state securities laws, this Agreement and all rights
hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Subject to such compliance, each taker and holder of this Agreement, by taking or
holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall
be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be
recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer
taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
 Each certificate representing shares acquired upon exercise of such Warrant shall bear a legend substantially in the following form: 
 “The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, and may not be
offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or an opinion of counsel satisfactory to the Company is obtained to the effect that such registration is not
required.” 
 SECTION 12. MISCELLANEOUS. 
 (a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This
Agreement shall be binding upon any successors or assigns of the Company. 
 (b) Remedies. In the event of any default
hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific
performance for any default where the non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party hereto expressly agrees that it shall not oppose an application by the other party or
any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining a party from continuing to commit any such breach of this Agreement. 
 (c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the
observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights
of the Warrantholder against impairment. 
 (d) Additional Documents. The Company, upon execution of this Agreement,
shall provide the Warrantholder with a certificate of an officer of the Company to the effect that the representations, warranties and covenants set forth in Sections 9(a) through 9(d),
 9(f) and 9(g). 
  

 10 









 Execution Version 
  

 The Company shall also supply such other documents as the Warrantholder may from time to time reasonably
request. 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the
Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’
fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding;
(iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 
 (f) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g) Notices. Except as otherwise
provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in
writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the first business day after transmission by facsimile or hand delivery or deposit with an overnight express service or overnight
mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 
 If to Warrantholder: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
 Legal Department 
 Attention: Chief Legal Officer 
 525 University Avenue, Suite 700 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 With a copy to: 
 BINGHAM MCCUTCHEN 
 Attn: John Connolly 
 Three Embarcadero Center 
 San Francisco, CA 94111 
 Facsimile: 415-393-2286 
 Telephone: 415-393-2560 
  

	 	(i)	If to the Company: 

 AVEO
PHARMACEUTICALS, INC. 
 Attention: President 
 75 Sidney Street 
 Fourth Floor 
 Cambridge, MA 02139 
 Facsimile: 617-995-4995 
 Telephone: 617-299-5000 
  

 11 









 Execution Version 
  

 With a copy to: 
 Wilmer Cutler Pickering Hale and Dorr LLP 
 Attention: Steven D. Singer, Esq. 
 60 State Street 
 Boston, MA 02109 
 Facsimile: 617-526-5000 
 Telephone: 617-526-6000 
 or to such other address as each party may designate for itself by like notice. 
 (h) Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals,
term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including Warrantholder’s proposal letter dated December 14, 2005 between the Warrantholder and the
Company). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 (i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 
 (j) Advice of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to
discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r). 
 (k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (l) No Waiver. No omission or delay by either party at any time to enforce any right or remedy reserved to it, or to require
performance of any of the terms, covenants or provisions hereof by the other party at any time designated, shall be a waiver of any such right or remedy to which such party is entitled, nor shall it in any way affect the right of such party to
enforce such provisions thereafter. 
 (m) Survival. All agreements, representations and warranties contained in this
Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 
 (n) Governing Law: This Agreement have been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by Warrantholder in the State of California. Delivery of Preferred Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
  

 12 









 Execution Version 
  

 (o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or
under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally:
(a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of
jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this
Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve
process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (p) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the
parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT
IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS
ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and
Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. 
 (q) Arbitration. If the Mutual Waiver of Jury Trial set forth in Section 12(p) is ineffective or unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in
accordance with the commercial arbitration rules of JAMS (the “Rules”), such arbitration to occur before one arbitrator, which arbitrator shall be a retired California state judge or a retired Federal court judge. Such proceeding shall be
conducted with California rules of evidence and discovery applicable to such arbitration. The decision of the arbitrator shall be binding on the parties, and shall be final and nonappealable to the maximum extent permitted by law. Any judgement
rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by the prevailing party as a final judgment of such court. 
 (r) Prearbitration Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction identified in Section 12(o), any prejudgment
order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration. 
 (s) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 
 (t) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue
to a party hereto by reason of the other party’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by either party hereto. If a party hereto institutes
any action or

  

 13 









 Execution Version 
  

 
proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party has an adequate
remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 [Remainder of Page intentionally Left Blank] 
  

 14 









 Execution Version 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

							
	COMPANY:	 		 	AVEO PHARMACEUTICALS, INC.
				
		 		 	By:	 	/s/ Tuan Ha-Ngoc
		 		 	Print Name:	 	Tuan Ha-Ngoc
		 		 	Title:	 	President and CEO
			
	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	/s/ Scott Harvey
		 		 	Print Name:	 	Scott Harvey
		 		 	Title:	 	Chief Legal Officer

  

 15 









 Execution Version 
  

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	AVEO Pharmaceuticals, Inc. (the “Company”) 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series [C/D]
Preferred Stock of the Company, pursuant to the terms of that certain Warrant Agreement, dated as of March 29, 2006, between the Company and the Warrantholder (the “Agreement”), and [CASH PAYMENT: tenders herewith payment of the
Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	In exercising its rights to purchase the Series [C/D] Preferred Stock of the Company, the undersigned, as representative for the Warrantholder, hereby confirms and
acknowledges the investment representations and warranties made in Section 10 of the Agreement. 

  

	(3)	Please issue a certificate or certificates representing said shares of Series [C/D] Preferred Stock in the name of the Warrantholder or in such other name as is
specified below. 

  

							
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	 
				
		 		 	Name:	 	 
				
		 		 	Title:	 	 
				
		 		 	Date:	 	 
				
		 		 	Address:	 	 
				
		 		 		 	 525 University Avenue, Suite 700
 Palo Alto, CA 94301
 Facsimile: 650-473-9194
 Telephone: 650-289-3060


  

 16 









 Execution Version 
  

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned, as representative of AVEO Pharmaceuticals, Inc. (the
“Company”), hereby acknowledges receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc. (the “Warrantholder”), to purchase
[            ] shares of the Series [C/D] Preferred Stock of the Company, pursuant to the terms of that certain Warrant Agreement, dated as of March 29, 2006, between the
Company and the Warrantholder (the “Agreement”), and further acknowledges that [            ] shares remain subject to purchase under the terms of the Agreement.

  

							
	 COMPANY:
	 		 	AVEO PHARMACEUTICALS, INC.
				
		 		 	By:	 	 
				
		 		 	Title:	 	 
				
		 		 	Date:	 	 

  

 17 









 Execution Version 
  

 EXHIBIT III 
 TRANSFER NOTICE 
 FOR VALUE RECEIVED, that certain Warrant Agreement, dated as of March 29,
2006, between AVEO Pharmaceuticals, Inc. and Hercules Technology Growth Capital, Inc., as the “Warrantholder (the “Agreement”), and all rights evidenced thereby are hereby transferred and assigned to 
 _________________________________________ 
 (Please
Print) 
 whose address is ____________________________ 
 __________________________________________ 
  

			
		
	Dated:	 	 
		
	Holder’s Signature:	 	 
		
	Holder’s Address:	 	 
	
	 


 Signature Guaranteed: _________________________ 
 The signature should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with
membership in an approved signature guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934. 
 NOTE:
The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other
representative capacity should file proper evidence of authority to assign the foregoing Agreement. 
  

 18